Clinical trials: Regression
Acute Coronary Artery Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT02347098)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- VA Office of Research and Development
Postoperative Pain
Decreasing Postoperative Pain Following Endometrial Ablation
To determine whether paracervical injection of long acting local anesthesia decreases postoperative pain following endometrial ablation under general anesthesia.
- Trial name
- NCT02660918
- Testing
- Bupivacaine, Normal Saline
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Christiana Care Health Services
Pyoderma Gangrenosum
Spesolimab in Pyoderma Gangrenosum
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum.
- Trial name
- NCT06092216
- Testing
- Spesolimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Type 1 Diabetes
Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
This study aims to compare the post-meal blood glucose values of two drugs in a "real-world" setting.
- Trial name
- NCT01621776
- Testing
- Apidra, Humalog, Novolog
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of Florida
Post-operative Urinary Retention
Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
Randomization (1:1) of male patients, over age 50, undergoing elective spine surgery to tamsulosin versus a placebo.
- Trial name
- DRIPS (NCT02919436)
- Testing
- Tamsulosin
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Anand Rughani, MD
Cardiovascular Disease
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Background: Cardiovascular disease (CVD) is a leading cause of death in developed countries. Although statin-type drugs are currently the most effective therapeutic agents for reducing CVD risk.
- Trial name
- NCT01131299
- Testing
- Alpha cyclodextrin
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Ileostomy - Stoma
Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications
The purpose of this study is to evaluate the efficacy of the Ostom-i device in decreasing readmission rates of subjects with new ileostomies in the first 30 days post-operatively.
- Trial name
- NCT02694757
- Testing
- Ostom-i device
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Overactive Bladder, Overactive Bladder Syndrome
OnabotulinumtoxinA Bladder Injection Study
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence
- Trial name
- NCT03523091
- Testing
- OnabotulinumtoxinA 100Unit Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Corewell Health East
Pain
Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation
This is a double blind, randomized, controlled study. The sedationist performing the sedation procedure will inject the appropriate amount of either a 1% Lidocaine solution or a placebo before the administration of Propofol.
- Trial name
- NCT02512783
- Testing
- Lidocaine, Normal Saline, Propofol
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Alcohol Use Disorder
Decreasing the Temporal Window in Individuals With Alcohol Use Disorder
In the absence of sufficient monetary resources, individuals must attend to immediate, minimum needs (e.g., food, shelter). This constricts one's temporal window and engenders neglect of the future.
- Trial name
- RP1B (NCT04128761)
- Testing
- Scarcity Narrative, Neutral Narrative
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Virginia Polytechnic Institute and State University
Labor Pain, Pregnancy
The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery
The objective of this study will be to compare epidural infusion management, specifically looking at infusion rate changes, in patients who receive forceps deliveries versus normal spontaneous vaginal deliveries.
- Trial name
- NCT00443560
- Testing
- Case controlled analysis of epidural labor analgesia patterns
- Where
- United States
- Volunteers
- 2,162 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Plaque, Gingivitis
A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation
The reduction of existing plaque and gum inflammation will be evaluated using two marketed mouth rinses along with tooth brushing after 21 days of use compared to a placebo mouth rinse.
- Trial name
- NCT02233998
- Testing
- Mouth Rinse 1, Mouth Rinse 2, Mouth Rinse 3
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
Background: Human epidermal growth factor receptor-2 (Her-2) is a gene found in both normal cells and cancer cells. Extra copies of the gene (overexpression) can cause too many Her-2 proteins (receptors) to appear on the cell…
- Trial name
- NCT00924287
- Testing
- in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Metastatic Melanoma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with melanoma that involves taking white blood cells from the patient, growing them in the laboratory in…
- Trial name
- NCT02062359
- Testing
- Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Background: gp100 is a protein that is often found in melanoma tumors. An experimental procedure developed for treating patients with melanoma uses anti-gp100 cells designed to destroy their tumors.
- Trial name
- NCT00610311
- Testing
- cyclophosphamide, fludarabine phosphate, Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Pain Due to Malignancy (Finding)
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
Cancer in general, and breast cancer in specific, is a significant health problem in the USA and the rest of the world. With the improvement of new surgical approaches and chemotherapies to manage breast cancer, the number of…
- Trial name
- NCT03847311
- Testing
- Sulfasalazine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals